- Home
- INDP vs CNVS Comparison
INDP vs CNVS Comparison
Compare INDP & CNVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDP
- CNVS
- Stock Information
- Founded
- INDP 2000
- CNVS 2000
- Country
- INDP United States
- CNVS United States
- Employees
- INDP N/A
- CNVS N/A
- Industry
- INDP Biotechnology: Pharmaceutical Preparations
- CNVS Consumer Electronics/Video Chains
- Sector
- INDP Health Care
- CNVS Consumer Discretionary
- Exchange
- INDP Nasdaq
- CNVS Nasdaq
- Market Cap
- INDP 6.0M
- CNVS N/A
- IPO Year
- INDP N/A
- CNVS 2003
- Fundamental
- Price
- INDP $12.00
- CNVS $6.75
- Analyst Decision
- INDP Strong Buy
- CNVS Buy
- Analyst Count
- INDP 2
- CNVS 1
- Target Price
- INDP $238.00
- CNVS $10.00
- AVG Volume (30 Days)
- INDP 698.6K
- CNVS 577.2K
- Earning Date
- INDP 08-11-2025
- CNVS 08-13-2025
- Dividend Yield
- INDP N/A
- CNVS N/A
- EPS Growth
- INDP N/A
- CNVS N/A
- EPS
- INDP N/A
- CNVS 0.16
- Revenue
- INDP N/A
- CNVS $78,181,000.00
- Revenue This Year
- INDP N/A
- CNVS N/A
- Revenue Next Year
- INDP N/A
- CNVS N/A
- P/E Ratio
- INDP N/A
- CNVS $42.41
- Revenue Growth
- INDP N/A
- CNVS 59.13
- 52 Week Low
- INDP $7.56
- CNVS $0.72
- 52 Week High
- INDP $66.64
- CNVS $7.39
- Technical
- Relative Strength Index (RSI)
- INDP 53.68
- CNVS 84.27
- Support Level
- INDP $9.45
- CNVS $3.72
- Resistance Level
- INDP $13.40
- CNVS $7.23
- Average True Range (ATR)
- INDP 2.17
- CNVS 0.56
- MACD
- INDP 0.20
- CNVS 0.22
- Stochastic Oscillator
- INDP 29.39
- CNVS 83.11
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.